Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia.
dysbindin-1 (DTNBP1)
pharmacogenetics
schizophrenia
tardive dyskinesia (TD)
Journal
Drug development research
ISSN: 1098-2299
Titre abrégé: Drug Dev Res
Pays: United States
ID NLM: 8204468
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
23
04
2020
received:
06
04
2020
accepted:
24
04
2020
pubmed:
13
5
2020
medline:
29
3
2022
entrez:
13
5
2020
Statut:
ppublish
Résumé
Tardive dyskinesia (TD) is a potentially irreversible movement disorder observed following long-term antipsychotic exposure. Its cause is unknown; however, a genetic component has been supported by studies of affected families. Dysbindin-1, encoded by the dystrobrevin-binding protein 1 DTNBP1 gene, has been associated with schizophrenia and is potentially involved in dopamine neurotransmission through its regulation of dopamine release and dopamine D2 receptor recycling, making it a candidate for investigation in TD. We investigated common variants across the DTNBP1 gene in our schizophrenia/patients with schizoaffective disorder of European ancestry. We found a number of DTNBP1 three-marker haplotypes to be associated with TD occurrence and TD severity (p < 0.05). These preliminary findings, if replicated in larger independent samples, would suggest that drugs targeting dysbindin-1 may be an option in the prevention and treatment of TD.
Substances chimiques
DTNBP1 protein, human
0
Dysbindin
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
678-684Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th edn)-text revision. Washington DC: American Psychiatric Association.
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005). Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics, 21(2), 263-265. https://doi.org/10.1093/bioinformatics/bth457
Basile, V. S., Masellis, M., Badri, F., Paterson, A. D., Meltzer, H. Y., Lieberman, J. A., … Kennedy, J. L. (1999). Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology, 21(1), 17-27. https://doi.org/10.1016/S0893-133X(98)00114-6
Browne, S., Roe, M., Lane, A., Gervin, M., Morris, M., Kinsella, A., … Callaghan, E. O. (1996). Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatrica Scandinavica, 94(2), 118-124.
Calle, M. L., Urrea, V., Malats, N., Van Steen, K. (2010). mbmdr: an R package for exploring gene-gene interactions associated with binary or quantitative traits. Bioinformatics, 26(17), 2198-2199.
Carbon, M., Hsieh, C. H., Kane, J. M., & Correll, C. U. (2017). Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: A meta-analysis. The Journal of Clinical Psychiatry, 78(3), e264-e278. https://doi.org/10.4088/JCP.16r10832
Carroll, B., & Irwin, D. E. (2019). Health care resource utilization and costs for patients with tardive dyskinesia. Journal of Managed Care & Specialty Pharmacy, 25(7), 810-816. https://doi.org/10.18553/jmcp.2019.25.7.810
Davis, M. C., Miller, B. J., Kalsi, J. K., Birkner, T., & Mathis, M. V. (2017). Efficient trial design - FDA approval of valbenazine for tardive dyskinesia. The New England Journal of Medicine, 376(26), 2503-2506. https://doi.org/10.1056/NEJMp1704898
Declaration of Helsinki (1989). https://www.wma.net/wp-content/uploads/2016/11/DoH-Sept1989.pdf
Dickman, D. K., & Davis, G. W. (2009). The schizophrenia susceptibility gene dysbindin controls synaptic homeostasis. Science, 326(5956), 1127-1130. https://doi.org/10.1126/science.1179685
Duan, J., Martinez, M., Sanders, A. R., Hou, C., Burrell, G. J., Krasner, A. J., … Gejman, P. V. (2007). DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: Association evidence in the 3′ end of the gene. Human Heredity, 64(2), 97-106. https://doi.org/10.1159/000101961
Duan, J., Wainwright, M. S., Comeron, J. M., Saitou, N., Sanders, A. R., Gelernter, J., & Gejman, P. V. (2003). Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Human Molecular Genetics, 12(3), 205-216.
Dudbridge, F. (2008). Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Human Heredity, 66(2), 87-98. https://doi.org/10.1159/000119108
Edwards, T. L., Wang, X., Chen, Q., Wormly, B., Riley, B., O'Neill, F. A., … Chen, X. (2008). Interaction between interleukin 3 and dystrobrevin-binding protein 1 in schizophrenia. Schizophrenia Research, 106(2-3), 208-217. https://doi.org/10.1016/j.schres.2008.07.022
Gauderman, W. J., & Morrison, J. M. (2006). QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies, http://hydra.usc.edu/gxe.
Gaysina, D., Cohen-Woods, S., Chow, P. C., Martucci, L., Schosser, A., Ball, H. A., … Farmer, A. (2009). Association of the dystrobrevin binding protein 1 gene (DTNBP1) in a bipolar case-control study (BACCS). American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 150(6), 836-844. https://doi.org/10.1002/ajmg.b.30906
Ghiani, C. A., Starcevic, M., Rodriguez-Fernandez, I. A., Nazarian, R., Cheli, V. T., Chan, L. N., … Dell'Angelica, E. C. (2010). The dysbindin-containing complex (BLOC-1) in brain: Developmental regulation, interaction with SNARE proteins and role in neurite outgrowth. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Molecular Psychiatry, 15(2), 115, 204-115. doi: https://doi.org/10.1038/mp.2009.58
Glazer, W. M., Morgenstern, H., & Doucette, J. (1994). Race and tardive dyskinesia among outpatients at a CMHC. Hospital and Community Psychiatry, 45(1), 38-42.
GTEx Consortium. (2013). The genotype-tissue expression (GTEx) project. [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural-U.S. Gov't]. Nature Genetics, 45(6), 580-585. https://doi.org/10.1038/ng.2653
Hirvonen, M. M., Laakso, A., Någren, K., Rinne, J. O., Pohjalainen, T., & Hietala, J. (2009). C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse, 63(10), 907-912.
Hirvonen, M. M., Lumme, V., Hirvonen, J., Pesonen, U., Någren, K., Vahlberg, T., … Hietala, J. (2009). C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 33(4), 630-636.
Iizuka, Y., Sei, Y., Weinberger, D. R., & Straub, R. E. (2007). Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. The Journal of Neuroscience, 27(45), 12390-12395. https://doi.org/10.1523/JNEUROSCI.1689-07.2007
Jain, R., & Correll, C. U. (2018). Tardive dyskinesia: Recognition, patient assessment, and differential diagnosis. The Journal of Clinical Psychiatry, 79(2), 16-23. https://doi.org/10.4088/JCP.nu17034ah1c
Jeste, D. V. (2000). Tardive dyskinesia in older patients. [Research Support, Non-U.S. Gov't]. The Journal of Clinical Psychiatry, 61(Suppl 4), 27-32.
Ji, Y., Yang, F., Papaleo, F., Wang, H. X., Gao, W. J., Weinberger, D. R., & Lu, B. (2009). Role of dysbindin in dopamine receptor trafficking and cortical GABA function. [Research Support, N.I.H., Intramural]. Proceedings of the National Academy of Sciences of the United States of America, 106(46), 19593-19598. https://doi.org/10.1073/pnas.0904289106
Kane, J. M., Correll, C. U., Nierenberg, A. A., Caroff, S. N., Sajatovic, M., & Tardive Dyskinesia Assessment Working, G. (2018). Revisiting the abnormal involuntary movement scale: Proceedings from the tardive dyskinesia assessment workshop. The Journal of Clinical Psychiatry, 79(3). pii: 17cs11959. https://doi.org/10.4088/JCP.17cs11959
Kumamoto, N., Matsuzaki, S., Inoue, K., Hattori, T., Shimizu, S., Hashimoto, R., … Tohyama, M. (2006). Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributed to the down-regulation of dysbindin. Biochemical and Biophysical Research Communications, 345(2), 904-909.
Lahiri, D. K., & Nurnberger, J. I., Jr. (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Research, 19(19), 5444.
Li, J., & Ji, L. (2005). Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb), 95(3), 221-227. https://doi.org/10.1038/sj.hdy.6800717
Müller, D. J., Schulze, T., Knapp, M., Held, T., Krauss, H., Weber, T., … Rietschel, M. (2001). Familial occurrence of tardive dyskinesia. Acta Psychiatrica Scandinavica, 104, 375-379.
Mullin, A. P., Sadanandappa, M. K., Ma, W., Dickman, D. K., VijayRaghavan, K., Ramaswami, M., … Faundez, V. (2015). Gene dosage in the dysbindin schizophrenia susceptibility network differentially affect synaptic function and plasticity. The Journal of Neuroscience, 35(1), 325-338. https://doi.org/10.1523/JNEUROSCI.3542-14.2015
Nagai, T., Kitahara, Y., Shiraki, A., Hikita, T., Taya, S., Kaibuchi, K., & Yamada, K. (2010). Dysfunction of dopamine release in the prefrontal cortex of dysbindin deficient sandy mice: An in vivo microdialysis study. [Research Support, Non-U.S. Gov't]. Neuroscience Letters, 470(2), 134-138. https://doi.org/10.1016/j.neulet.2009.12.071
Numakawa, T., Yagasaki, Y., Ishimoto, T., Okada, T., Suzuki, T., Iwata, N., … Hashimoto, R. (2004). Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Human Molecular Genetics, 13(21), 2699-2708.
Nyholt, D. R. (2004). A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. American Journal of Human Genetics, 74(4), 765-769. https://doi.org/10.1086/383251
Ramasamy, A., Trabzuni, D., Guelfi, S., Varghese, V., Smith, C., Walker, R., … Weale, M. E. (2014). Genetic variability in the regulation of gene expression in ten regions of the human brain. Nature Neuroscience, 17(10), 1418-1428. https://doi.org/10.1038/nn.3801
Ricciardi, L., Pringsheim, T., Barnes, T. R. E., Martino, D., Gardner, D., Remington, G., … Edwards, M. (2019). Treatment recommendations for tardive dyskinesia. Canadian Journal of Psychiatry, 64(6), 388-399. https://doi.org/10.1177/0706743719828968
Schooler, N. R., & Kane, J. M. (1982). Research diagnoses for tardive dyskinesia. Archives of General Psychiatry, 39(4), 486-487.
Schwab, S. G., Knapp, M., Mondabon, S., Hallmayer, J., Borrmann-Hassenbach, M., Albus, M., … Wildenauer, D. B. (2003). Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. American Journal of Human Genetics, 72(1), 185-190. https://doi.org/10.1086/345463
Scorr, L. M., & Factor, S. A. (2018). VMAT2 inhibitors for the treatment of tardive dyskinesia. Journal of the Neurological Sciences, 389, 43-47. https://doi.org/10.1016/j.jns.2018.02.006
Shao, L., Shuai, Y., Wang, J., Feng, S., Lu, B., Li, Z., … Zhong, Y. (2011). Schizophrenia susceptibility gene dysbindin regulates glutamatergic and dopaminergic functions via distinctive mechanisms in drosophila. Proceedings of the National Academy of Sciences of the United States of America, 108(46), 18831-18836. https://doi.org/10.1073/pnas.1114569108
Shi, J., Badner, J. A., Gershon, E. S., & Liu, C. (2008). Allelic association of G72/G30 with schizophrenia and bipolar disorder: A comprehensive meta-analysis. Schizophrenia Research, 98(1-3), 89-97. https://doi.org/10.1016/j.schres.2007.10.004
Smith, C. T., Dang, L. C., Buckholtz, J. W., Tetreault, A. M., Cowan, R. L., Kessler, R. M., & Zald, D. H. (2017). The impact of common dopamine D2 receptor gene polymorphisms on D2/3 receptor availability: C957T as a key determinant in putamen and ventral striatum. Translational Psychiatry, 7(4), e1091.
Solmi, M., Pigato, G., Kane, J. M., & Correll, C. U. (2018). Clinical risk factors for the development of tardive dyskinesia. Journal of the Neurological Sciences, 389, 21-27.
Straub, R. E., Jiang, Y., MacLean, C. J., Ma, Y., Webb, B. T., Myakishev, M. V., … Kendler, K. S. (2002). Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. American Journal of Human Genetics, 71(2), 337-348. https://doi.org/10.1086/341750
Takao, K., Toyama, K., Nakanishi, K., Hattori, S., Takamura, H., Takeda, M., … Hashimoto, R. (2008). Impaired long-term memory retention and working memory in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Molecular Brain, 1, 11. https://doi.org/10.1186/1756-6606-1-11
Talbot, K., Eidem, W. L., Tinsley, C. L., Benson, M. A., Thompson, E. W., Smith, R. J., … Arnold, S. E. (2004). Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. The Journal of Clinical Investigation, 113(9), 1353-1363. https://doi.org/10.1172/JCI20425
Tang, J., LeGros, R. P., Louneva, N., Yeh, L., Cohen, J. W., Hahn, C. G., … Talbot, K. (2009). Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. Human Molecular Genetics, 18(20), 3851-3863. https://doi.org/10.1093/hmg/ddp329
Trantham-Davidson, H., & Lavin, A. (2019). Loss of dysbindin-1 affects GABAergic transmission in the PFC. Psychopharmacology, 236(11), 3291-3300. https://doi.org/10.1007/s00213-019-05285-1
Voisey, J., Swagell, C. D., Hughes, I. P., Connor, J. P., Lawford, B. R., Young, R. M., & Morris, C. P. (2010). A polymorphism in the dysbindin gene (DTNBP1) associated with multiple psychiatric disorders including schizophrenia. Behavioral and Brain Functions, 6, 41. https://doi.org/10.1186/1744-9081-6-41
Wang, H., Xu, J., Lazarovici, P., & Zheng, W. (2017). Dysbindin-1 involvement in the etiology of schizophrenia. International Journal of Molecular Sciences, 18(10), pii: E2044. https://doi.org/10.3390/ijms18102044
Weinhold, P., Wegner, J. T., & Kane, J. M. (1981). Familial occurrence of tardive dyskinesia. The Journal of Clinical Psychiatry, 42, 165-166.
Widschwendter, C. G., & Hofer, A. (2019). Antipsychotic-induced tardive dyskinesia: Update on epidemiology and management. Current Opinion in Psychiatry, 32(3), 179-184. https://doi.org/10.1097/YCO.0000000000000491
Yang, W., Zhu, C., Shen, Y., & Xu, Q. (2016). The pathogenic mechanism of dysbindin-1B toxic aggregation: BLOC-1 and intercellular vesicle trafficking. Neuroscience, 333, 78-91. https://doi.org/10.1016/j.neuroscience.2016.07.008
Yassa, R., & Ananth, J. (1981). Familial tardive dyskinesia. The American Journal of Psychiatry, 138, 1618-1619.
Zai, C., Tiwari, A., Basile, V., De Luca, V., Muller, D., King, N., … Kennedy, J. (2009). Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. The Pharmacogenomics Journal, 9, 168-174.
Zai, C. C., Hwang, R. W., De Luca, V., Muller, D. J., King, N., Zai, G. C., … Kennedy, J. L. (2007). Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. The International Journal of Neuropsychopharmacology, 10, 639-651.
Zai, C. C., Lee, F. H., Tiwari, A. K., Lu, J. Y., de Luca, V., Maes, M. S., … Kennedy, J. L. (2018). Investigation of the HSPG2 gene in Tardive Dyskinesia - new data and meta-analysis. Frontiers in Pharmacology, 9, 974. https://doi.org/10.3389/fphar.2018.00974
Zai, C. C., Maes, M. S., Tiwari, A. K., Zai, G. C., Remington, G., & Kennedy, J. L. (2018). Genetics of tardive dyskinesia: Promising leads and ways forward. Journal of the Neurological Sciences, 389, 28-34. https://doi.org/10.1016/j.jns.2018.02.011
Zai, C. C., Tiwari, A. K., Mazzoco, M., De Luca, V., Muller, D. J., Shaikh, S. A., … Kennedy, J. L. (2013). Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. Journal of Psychiatric Research, 47, 1760-1765.
Zuo, L., Luo, X., Krystal, J. H., Cramer, J., Charney, D. S., & Gelernter, J. (2009). The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenetics and Genomics, 19(6), 437-446. https://doi.org/10.1097/FPC.0b013e32832b9cfc